Who Paid My Doc
Laurel Wills
Developmental - Behavioral Pediatrics Minneapolis, MN Medical Doctor
NPI 1962416313 CMS profile 931736
701 Park Ave, G7, Minneapolis, MN 55415
General payments
$106
Research payments
$0
Ownership & investment interest
$0
Through program year 2022, Laurel Wills of Minneapolis, MN is reported in the CMS Open Payments database as having received $106 across 2 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 46th percentile of Developmental - Behavioral Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
2 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2022 | General | $34 | 1 | |
| 2020 | General | $72 | 1 |
Beside peers
- Laurel Wills
- Developmental - Behavioral Pediatrics median
- Middle half of Developmental - Behavioral Pediatrics
- National median
In program year 2025, general payments to Laurel Wills were reported at $0. Among 160 Developmental - Behavioral Pediatrics profiles paid that year, the median was $77 and the middle half received between $27 and $211.
Show as a table
| Year | Laurel Wills | Developmental - Behavioral Pediatrics median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $106 | $28–$315 | $163 |
| 2020 | $72 | $55 | $19–$181 | $114 |
| 2021 | $0 | $96 | $25–$343 | $132 |
| 2022 | $34 | $86 | $23–$235 | $149 |
| 2023 | $0 | $71 | $25–$348 | $160 |
| 2024 | $0 | $74 | $25–$237 | $164 |
| 2025 | $0 | $77 | $27–$211 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 4 drugsPart D claims
71
Drug cost
$6,936
Branded share of claims
31%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Aripiprazole | Generic | 12 | $3,935 | |
| Guanfacine Hcl Er Guanfacine Hcl | Brand | 22 | $2,655 | |
| Fluoxetine Hcl | Generic | 24 | $221 | |
| Trazodone Hcl | Generic | 13 | $124 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,361 Part D prescribers listed as Pediatric Medicine; they describe a distribution and say nothing about conduct.
Records
2 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Developmental - Behavioral Pediatrics in Minnesota
Related records
Developmental - Behavioral Pediatrics in Minnesota
Practitioners in the same specialty and state, ranked by reported value.
All Developmental - Behavioral Pediatrics
Everyone recorded under this specialty, nationwide.
Doctors in Minnesota
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.